1 citations
,
April 2006 in “International Journal of Oncology” Lysocellin helps stop cell damage from etoposide and may prevent hair loss.
April 2023 in “Medicina Clínica (english Edition)”
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
10 citations
,
August 2016 in “Dermatology Online Journal” Nilotinib can cause skin issues like red bumps and hair loss.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
June 2015 in “Reactions weekly” December 2012 in “Reactions weekly”
196 citations
,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
May 2024 in “Reactions weekly”
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.
16 citations
,
May 2022 in “New England Journal of Medicine” Baricitinib is not very effective for severe alopecia areata.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
January 2012 in “Zhongguo quanke yixue” The treatment was effective and tolerable for advanced gastric cancer.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
September 2023 in “HAL (Le Centre pour la Communication Scientifique Directe)” Peptide nanoparticles can effectively deliver CRISPR-Cas9 to target KRAS mutations in cancer.
38 citations
,
October 2005 in “Expert opinion on therapeutic patents” Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.
4 citations
,
February 2025 in “Pharmaceuticals” Voglibose may help treat skin hyperpigmentation safely.
January 2024 in “Case Reports in Dermatological Medicine” Baricitinib may effectively treat nail changes in alopecia areata.
January 2025 in “Frontiers in Pediatrics” Baricitinib significantly improved hair regrowth and skin condition in a 14-year-old with alopecia areata and atopic dermatitis.